https://kstockbriefing.com
Fact Source: Financial Supervisory Service DART 💡 Executive Summary Hanwha Aerospace filed a corrective disclosure confirming that Hanwha Systems USA Corporation, a 100% owned subsidiary of Hanwha Systems Co., Ltd. (which is a subsidiary of Hanwha Aerospace), finalized its paid-in capital increase of approximately KRW 427.91B on December 22, 2025. 📊 [Key Disclosure Contents &…
Fact Source: Financial Supervisory Service DART 💡 Executive Summary Hanwha Aerospace filed a corrective disclosure as Hanwha Ocean USA Holdings Corp., a 100% owned subsidiary of Hanwha Ocean Co., Ltd. (which is a subsidiary of Hanwha Aerospace), completed payment for its paid-in capital increase of approximately KRW 153.2B on December 22, 2025. 📊 [Key Disclosure…
![[Disclosure] Samsung Biologics (207940) – Decision on Acquisition of Shares and Equity Securities of Other Corporations (Voluntary Disclosure) / 2025-12-22](https://kstockbriefing.com/wp-content/uploads/2026/07/포맷변환-삼성바이오로직스.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has voluntarily disclosed that its 100% subsidiary, Samsung Biologics America, Inc., resolved to acquire 100% shares of US-based Human Genome Sciences Inc. from GSK for approximately KRW 413.6B to secure local drug substance manufacturing facilities. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has voluntarily disclosed a pharmaceutical contract manufacturing agreement worth approximately KRW 56.7B with a pharmaceutical company based in Europe. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking Revenue and Earnings Recognition Over Contract Period This disclosure was…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has voluntarily disclosed a pharmaceutical contract manufacturing agreement worth approximately KRW 56.1B with a pharmaceutical company based in Europe. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking Revenue and Earnings Recognition Over Contract Period This disclosure was…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed a pharmaceutical contract manufacturing agreement worth approximately KRW 1.11T with a pharmaceutical company based in Europe. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking Revenue Recognition for Large-Scale Manufacturing Agreement This disclosure represents a major…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Systems submitted a corrected disclosure modifying the scheduled acquisition date (payment date) to December 22, 2025, for its acquisition of shares in wholly owned subsidiary Hanwha Systems USA Corporation (valued at approx. KRW 427.9B). 📊 [Key Disclosure Contents & Summary of Key Figures] 📝 Editor’s…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Systems submitted a corrected disclosure modifying the payment date to December 22, 2025, for the rights offering of its wholly owned subsidiary Hanwha Systems USA Corporation (raising approx. KRW 427.9B to acquire securities of another corporation). 📊 [Key Disclosure Contents & Summary of Key Figures]…
![[Disclosure] Hanwha Ocean (042660) – Sales and Supply Contract / 2025-12-19](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환한화오션.jpg)
Fact Source: Financial Supervisory Service DART 💡 Executive Summary Hanwha Ocean secured a major contract worth KRW 2.5891T (24.0% of recent annual revenue) to construct seven LNG carriers (LNGC) for a European shipowner. 📊 [Key Disclosure Details & Financial Summary] 1. Contract Overview 2. Financial Details & Scale 3. Contract Terms & Schedule 📝 Editor’s…
Read More “[Disclosure] Hanwha Ocean (042660) – Sales and Supply Contract / 2025-12-19” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Yoon OO and 1,230 minority shareholders (1.71% stake) have filed a lawsuit against Celltrion seeking court permission to convene an Extraordinary General Meeting of Shareholders regarding treasury share cancellation, articles amendment, and director dismissal. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up…